We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
+$224M
Cap. Flow %
9.21%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.86%
2 Healthcare 14.52%
3 Energy 1.33%
4 Technology 0.46%
5 Materials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
276
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$567K 0.02%
+140
New +$7.42K
ESPR
277
DELISTED
Esperion Therapeutics
ESPR
$566K 0.02%
+23,990
New +$1.51M
RLYP
278
CALL
DELISTED
RELYPSA INC COM
RLYP
$555K 0.02%
+300
New +$8.24K
LXRX icon
279
CALL
Lexicon Pharmaceuticals
LXRX
$894M
$548K 0.02%
+510
New +$5.57K
ALNY icon
280
Alnylam Pharmaceuticals
ALNY
$31.9B
$547K 0.02%
+6,809
New +$757K
ETRM
281
DELISTED
EnteroMedics Inc.
ETRM
$536K 0.02%
1,965
+393
+25% +$125K
REGN icon
282
Regeneron Pharmaceuticals
REGN
$79.7B
$535K 0.02%
+1,150
New +$618K
BITI
283
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$524K 0.02%
+40,000
New +$703K
KYNB
284
Kyntra Bio
KYNB
$31.5M
$517K 0.02%
944
-2,980
-76% -$1.81M
SCON
285
DELISTED
Superconductor Technologies Inc.
SCON
$494K 0.02%
531
-597
-53% -$916K
LAB icon
286
CALL
Standard BioTools
LAB
$271M
$488K 0.02%
3,617
+3,172
+713% +$49.9K
SGYPW
287
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$486K 0.02%
291,206
-5,400
-2% -$19K
PGNX
288
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$480K 0.02%
840
+231
+38% +$1.77K
ABUS icon
289
CALL
Arbutus Biopharma
ABUS
$1B
$479K 0.02%
787
+130
+20% +$1.15K
PTLA
290
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$477K 0.02%
+11,201
New +$540K
BLCM
291
PUT
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$472K 0.02%
33
– –
ATRS
292
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$466K 0.02%
+2,742
New +$5.38K
LITS
293
Lite Strategy Inc
LITS
$37.1M
$464K 0.02%
14,775
– –
OMER icon
294
Omeros
OMER
$1.24B
$464K 0.02%
+42,377
New +$660K
ACGN
295
DELISTED
Aceragen Inc
ACGN
$461K 0.02%
127
+106
+505% +$375K
NVO
296
PUT
Novo Nordisk
NVO
$188B
$456K 0.02%
168
– –
CSLT
297
CALL
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$447K 0.02%
1,065
-1,084
-50% -$6.84K
BDSI
298
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$439K 0.02%
789
– –
ADVM
299
CALL
DELISTED
Adverum Biotechnologies
ADVM
$437K 0.02%
+53
New +$6.77K
ALBO
300
DELISTED
Albireo Pharma Inc
ALBO
$433K 0.02%
32,789
-5,524
-14% -$139K
10 11
12
13 14

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.